News UK's Mission divests kidney drug to Dimerix for $292m Mission Therapeutics has struck a deal to out-license a drug for acute kidney injury to Australia's Dimerix, sharpening its focus on CNS diseases.
News Biogen, Denali pull Parkinson's drug after failed trial Biogen has stopped development of Denali-partnered Parkinson's disease candidate BIIB122, after it failed to move the needle in a phase 2b trial.
News Remepy's hybrid Parkinson's therapy poised for phase 3 Remepy's Hybridopa therapy for Parkinson's, which combines an app with levodopa therapy, has shown efficacy in a phase 2 pilot study.
News Cellular Intelligence scoops up Novo's Parkinson's therapy Novo Nordisk has sold the rights to one of the flagship candidates in its now-defunct cell therapy unit to AI start-up Cellular Intelligence.
News AI-powered study finds multiple Parkinson’s types Researchers have used a machine learning algorithm to try to work out why Parkinson's disease patients can respond so differently to treatment.
News New NIHR-funded TRC for Parkinson’s disease The launch of a new national research collaboration focused on Parkinson’s disease has been announced.
News UK's Mission divests kidney drug to Dimerix for $292m Mission Therapeutics has struck a deal to out-license a drug for acute kidney injury to Australia's Dimerix, sharpening its focus on CNS diseases.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.